A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

NCT05819710 ↗

Phase 1 Completed 43 enrolled Taisho Pharmaceutical Co., Ltd.

RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a study to investigate the next-day residual effects of a single bedtime dosing of 5 mg and 10 mg of TS-142 in Japanese healthy elderly participants in double-blind manner.

Timeline

Start: 2023-05-15
Primary completion: 2023-08-25
Completion: 2023-08-25

Publications

Miyazaki Y, Kambe D, Imadera Y, Yamasaki H, Uchimura N, Uchiyama M. Comparison of next-morning residual effects by bedtime administration of vornorexant and zopiclone in healthy older participants: postural stability, neuropsychological functions, and subjective sleepiness in a randomized clinical study. Psychopharmacology (Berl). 2026 May 23. doi: 10.1007/s00213-026-07095-8. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TS-142	Small molecule	5 mg	—
Subject	TS-142	Small molecule	10 mg	—
Subject	Zopiclone	Small molecule	7.5 mg	—

Indications

No indication recorded.